The results of an international, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic cerebral ischemia (the MEMO study), conducted in full compliance with international ethical and scientific standards for the design and conduct of research involving human subjects (GCP), were published in the Korsakov Journal of Neurology and Psychiatry, 2021; 121(11):7–16, a leading peer-reviewed journal for neurologists and psychiatrists in Russia, recognized by the Higher Attestation Commission (HAC).
To fully utilize the therapeutic potential of Mexidol®, sequential long-term therapy is recommended (EPICA1, 2017): initially 14 days of injections (saturation phase), followed by a transition to Mexidol® or Mexidol® FORTE 250 tabletsfor 2months (therapeutic effect maximization phase). Therapy is administered 2-3 times per year or during periods of exacerbation.
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com